ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Unfortunately, in a number of patients, IM has a lower efficiency in the advanced stages of CML due to the apparition of mutations that amplify the BCR-ABL gene expression and thus the development of IM resistance.